Clinical trials: Type1 Diabetes
Type1 Diabetes Mellitus
Mechanisms for Restoration of Hypoglycemia Awareness
To assess if using the hypoglycemic clamp and functional magnetic resonance imaging (fMRI) scanning in hypoglycemia unaware and aware T1DM patients and healthy controls have showed distinct differences in patterns of brain…
- Trial name
- NCT03738852
- Testing
- Continuous Glucose Monitor (CGM), Insulin
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Yale University
Type 1 Diabetes
Three-way, Cross-over Closed-loop Exercise Study
Blood glucose control systems that utilize both insulin and glucagon to manage blood sugar are paving the way to revolutionize the management of this disease.
- Trial name
- NCT02241889
- Testing
- Insulin pump therapy, Closed-loop Artificial Pancreas Controller
- Where
- United States
- Volunteers
- 23 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Diabetes Mellitus, Type 1
Safety And Efficacy Of Exubera Compared With Subcutaneous Human Insulin Therapy In Children And Adolescents
To assess the safety and efficacy of Exubera on pulmonary function and glycemic control in subjects ages 6-17 over a 1 year period.
- Trial name
- NCT00479258
- Testing
- Inhaled insulin (Exubera), Subcutaneous Insulin (subject's prescribed)
- Where
- United States
- Volunteers
- 2 people
- Sponsor
- Pfizer
Type 1 Diabetes Mellitus
Initiation of Continuous Glucose Monitoring at Diagnosis of Type 1 Diabetes
The purpose of this study is to learn about the impact of continuous glucose monitoring (CGM) on families with newly diagnosed children with type 1 diabetes (T1D).
- Trial name
- NCT02734667
- Testing
- CGM at diagnosis of T1D
- Where
- 2 sites in United States
- Volunteers
- 120 people
- Sponsor
- Korey Hood
Diabetes Mellitus, Type 1
Sensor-augmented Pump Versus Multiple Daily Injections With Degludec as Basal Insulin for Insulin Therapy in Type 1 Diabetes
Several studies have shown that Continuous Subcutaneous Insulin Infusion together with Continuous Glucose Monitoring improves glycemic control in type 1 diabetes when compared to more traditional approaches; however, in available…
- Trial name
- NCT03557892
- Testing
- CGM+CSII, MDI with degludec
- Where
- Italy
- Volunteers
- 28 people
- Sponsor
- Azienda Ospedaliero-Universitaria Careggi
Prediabetes, Type 1 Diabetes
Diabetes Prevention - Immune Tolerance
A double-blind, randomized investigator-initiated study to determine the safety and the effect of Diamyd® on the progression to type 1 diabetes in children with multiple islet cell autoantibodies Eligible children are 4 years or…
- Trial name
- DIAPREV-IT (NCT01122446)
- Testing
- Diamyd
- Where
- Sweden
- Volunteers
- 50 people
- Sponsor
- Lund University
Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes
Teplizumab for Prevention of Type 1 Diabetes In Relatives "At-Risk"
The study will determine whether the anti-CD3 monoclonal antibody, teplizumab, can help to prevent or delay the onset of type 1 diabetes (T1D) in relatives determined to be at very high risk for developing the disease.
- Conditions
- Autoantibody Positive, Non-diabetic Relatives at Risk for Type 1 Diabetes, High Risk, Impaired Glucose Tolerance
- Trial name
- NCT01030861
- Testing
- Teplizumab
- Where
- 19 sites in United States, Canada and 1 more
- Volunteers
- 76 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes, Type 1
Safety and Efficacy of Technosphere® Insulin Inhalation Powder and Lantus® Compared to Humalog® and Lantus® Over 16-Weeks
The objective of this study is to demonstrate that TI® Inhalation Powder combined with Lantus® is as effective as Humalog® combined with Lantus® on HbA1c.
- Trial name
- NCT00700622
- Testing
- Technosphere Insulin, Insulin glargine, Insulin lispro
- Where
- 22 sites in United States, Brazil
- Volunteers
- 130 people
- Sponsor
- Mannkind Corporation
Type 1 Diabetes Mellitus, Type 2 Diabetes Mellitus
Multiple Ascending Dose Study of MK-5160 in Participants With Type 1 and Type 2 Diabetes Mellitus (MK-5160-002)
This is a randomized, active- and placebo-controlled, double-blind trial of MK-5160 in participants with Type 1 diabetes mellitus (T1DM) and Type 2 diabetes mellitus (T2DM). This is a two-part trial, with three panels per part.
- Trial name
- NCT03095651
- Testing
- MK-5160 16 nmol/kg, MK-5160 32 nmol/kg, MK-5160 64 nmol/kg
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Merck Sharp & Dohme LLC
Type 1 Diabetes
Four Way Crossover Closed Loop With Exercise Detection
Closed-loop systems are an emerging technology that automate hormone delivery. They are quickly paving the way to revolutionize the treatment of type 1 diabetes.
- Trial name
- NCT02862730
- Testing
- Artificial Pancreas Controller in Dual Hormone Mode, Subject's insulin pump, Artificial Pancreas Controller in Single Hormone Mode
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- Oregon Health and Science University
Type 1 Diabetes Mellitus
A Study of LY3209590 in Participants With Type 1 Diabetes
The reason for this study is to see if the study drug LY3209590 is safe and effective in participants with type 1 diabetes.
- Trial name
- NCT04450407
- Testing
- LY3209590, Insulin Degludec
- Where
- 54 sites in United States, Austria and 3 more
- Volunteers
- 266 people
- Sponsor
- Eli Lilly and Company
Abnormal Glucose Tolerance, Type 1 Diabetes
CTLA4-Ig (Abatacept)for Prevention of Abnormal Glucose Tolerance and Diabetes in Relatives At -Risk for Type 1
The study is a 2-arm, multicenter, 1:1 randomized, placebo controlled clinical trial. All subjects will receive close monitoring for development of AGT or T1DM.
- Trial name
- NCT01773707
- Testing
- CTLA4-Ig (Abatacept)
- Where
- 17 sites in United States, Canada
- Volunteers
- 212 people
- Sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Afrezza® Dosing Optimization Study
MKC-TI-191 is a Phase 4, single-arm, multicenter, proof-of-concept clinical trial evaluating the efficacy and safety of Afrezza, administered according to the current Afrezza prescribing information (PI) compared to a titrated…
- Trial name
- DOS (NCT04849845)
- Testing
- Afrezza Dose 1, Afrezza Dose 2
- Where
- 2 sites in United States
- Volunteers
- 20 people
- Sponsor
- Mannkind Corporation
Type 1 Diabetes Mellitus
Detemir: Role in Type 1 Diabetes
Study of blood sugars in the children with Type 1 Diabetes Mellitus (T1DM), who are given insulin detemir and a rapid acting insulin (aspart).
- Trial name
- NCT00564395
- Testing
- Insulin Detemir mixed with RAI injection, Insulin Detemir and RAI injection
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Montefiore Medical Center
Diabetes, Diabetes Mellitus, Type 1
The Efficacy and Safety of Liraglutide Adjunct to Insulin Treatment in Type 1 Diabetes
This trial is conducted in Africa, Europe and North America. The purpose of the trial is to investigate the efficacy and safety of liraglutide adjunct to insulin treatment in type 1 diabetes.
- Trial name
- ADJUNCT TWO™ (NCT02098395)
- Testing
- liraglutide
- Where
- 120 sites in United States, Austria and 11 more
- Volunteers
- 835 people
- Sponsor
- Novo Nordisk A/S
Type 1 Diabetes
Diabetes Strengths Study - Pilot of Provider-delivered Strengths-based Intervention
The purpose of this study is to determine whether a newly developed intervention is feasible and acceptable to adolescents with type 1 diabetes and their families and diabetes care providers, and to evaluate trends in whether the…
- Trial name
- DSS (NCT02510664)
- Testing
- Diabetes Strengths Study
- Where
- United States
- Volunteers
- 172 people
- Sponsor
- Baylor College of Medicine
Type 1 Diabetes Mellitus
Improving Health Communication During the Transition From Pediatric to Adult Diabetes Care
Adolescents and young adults (AYAs; ages 17-23) with type 1 diabetes are at high risk for negative health outcomes, including poor glycemic control and disengagement from the health care system.
- Trial name
- NCT03734107
- Testing
- Plan, Reflect, and Engage with Providers for Diabetes Care
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Children's National Research Institute
Diabetes, Diabetes Mellitus, Type 1
Comparison of NN1250 Plus Insulin Aspart With Insulin Glargine Plus Insulin Aspart in Type 1 Diabetes
This trial is conducted in Africa, Europe and the United States of America (USA). The aim of the trial is to compare NN1250 (insulin degludec, soluble insulin basal analogue (SIBA)) plus insulin aspart with insulin glargine…
- Trial name
- BEGIN™ (NCT00982228)
- Testing
- insulin degludec, insulin glargine, insulin aspart
- Where
- 91 sites in United States, France and 4 more
- Volunteers
- 629 people
- Sponsor
- Novo Nordisk A/S
Diabetes Mellitus, Type 1
Empa Add on to Insulin in Japanese Patient With Type 1 Diabetes Mellitus
To assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of once daily oral doses of empagliflozin in Japanese patients with type 1 diabetes mellitus as adjunctive therapy to insulin.
- Trial name
- NCT02702011
- Testing
- empagliflozin medium dose, empagliflozin low dose, empagliflozin high dose
- Where
- 4 sites in Japan
- Volunteers
- 48 people
- Sponsor
- Boehringer Ingelheim
Diabetes, Diabetes Mellitus, Type 1
Observational Study to Evaluate the Safety of Levemir® in Diabetes
This study is conducted in Africa, Asia, Europe, Japan and South America. The aim of this observational study is to evaluate the incidence of serious adverse reactions (SARs) while using Levemir® (insulin detemir) under normal…
- Conditions
- Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
- Trial name
- PREDICTIVE™ (NCT00659295)
- Testing
- insulin detemir
- Where
- 13 sites in Belgium, Czechia and 11 more
- Volunteers
- 51,170 people
- Sponsor
- Novo Nordisk A/S